Brokerages Set IQVIA Holdings Inc. (NYSE:IQV) Target Price at $225.69

Shares of IQVIA Holdings Inc. (NYSE:IQV) have earned a consensus rating of “Buy” from the seventeen analysts that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $225.6875.

A number of equities research analysts have issued reports on IQV shares. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and increased their price target for the company from $174.00 to $213.00 in a research report on Monday, March 9th. Jefferies Financial Group cut their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday, April 19th. Evercore reissued an “outperform” rating and set a $185.00 target price on shares of IQVIA in a research report on Wednesday, April 8th. Finally, Mizuho set a $215.00 target price on IQVIA in a research report on Monday, February 23rd.

IQVIA Price Performance

IQV stock opened at $172.86 on Friday. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The firm has a market capitalization of $28.85 billion, a P/E ratio of 21.42, a P/E/G ratio of 1.62 and a beta of 1.18. The business’s 50-day moving average is $170.03 and its two-hundred day moving average is $198.74. IQVIA has a 1 year low of $134.65 and a 1 year high of $247.04.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. The company had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.IQVIA’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter last year, the company earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Analysts anticipate that IQVIA will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a stock repurchase program on Thursday, May 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its shares are undervalued.

Institutional Investors Weigh In On IQVIA

Hedge funds and other institutional investors have recently made changes to their positions in the business. Brighton Jones LLC increased its position in IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after buying an additional 2,537 shares during the period. Empowered Funds LLC increased its position in IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after buying an additional 4,915 shares during the period. Sivia Capital Partners LLC acquired a new position in IQVIA during the second quarter worth approximately $514,000. First Trust Advisors LP increased its position in IQVIA by 14.8% during the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock worth $14,501,000 after buying an additional 11,845 shares during the period. Finally, NewEdge Advisors LLC increased its position in IQVIA by 5.4% during the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after buying an additional 1,155 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.